As Wall Street navigates the complexities of tariffs and Federal Reserve Chair Jerome Powell's testimony, the U.S. stock market remains a mixed bag with indices showing varied performance. Amid these broader economic discussions, penny stocks continue to capture investor interest by offering potential growth opportunities at lower price points. While often associated with smaller or newer companies, these stocks can present compelling prospects when backed by strong financials and solid fundamentals, making them noteworthy candidates for investors seeking hidden gems in today's market landscape.

Click here to see the full list of 717 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions for diabetes treatment and orally ingestible capsules for polypeptide delivery, with a market cap of $87.48 million.

Operations: Oramed Pharmaceuticals Inc. has not reported any specific revenue segments.

Market Cap: $87.48M

Oramed Pharmaceuticals Inc., with a market cap of US$87.48 million, is pre-revenue and has recently become profitable, although its earnings growth rate is challenging to compare due to this recent profitability. The company is debt-free and has not diluted shareholders in the past year. Its management and board are experienced, with average tenures of 12.2 years and 8.4 years respectively. While short-term assets significantly exceed both short- and long-term liabilities, future earnings are forecasted to decline substantially over the next three years despite anticipated revenue growth of 256.94% annually.

Simply Wall St Financial Health Rating: ★★★★★☆